<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Original Research Epidemiology, Outcome and Risk Factors Analysis of" exact="Viral" post="Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation:"/>
 <result pre="Original Research Epidemiology, Outcome and Risk Factors Analysis of Viral" exact="Infections" post="in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral"/>
 <result pre="Reactivation Czyzewski et al Czyzewski et al http://orcid.org/0000-0001-7704-7518CzyzewskiKrzysztof1DziedzicMagdalena1SalamonowiczMalgorzata2http://orcid.org/0000-0002-8467-8788FraczkiewiczJowita2http://orcid.org/0000-0002-8836-8605Zajac-SpychalaOlga3Zaucha-PrazmoAgnieszka4GozdzikJolanta5http://orcid.org/0000-0002-8227-8350GalazkaPrzemyslaw6BartoszewiczNatalia1DemidowiczEwa1http://orcid.org/0000-0002-3158-119XStyczynskiJan1[1], Department of" exact="Pediatric" post="Hematology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus"/>
 <result pre="Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunBydgoszczPoland[2], Department of" exact="Pediatric" post="Transplantation, Oncology and Hematology, Medical UniversityWroclawPoland[3], Department of Pediatric"/>
 <result pre="of Pediatric Transplantation, Oncology and Hematology, Medical UniversityWroclawPoland[3], Department of" exact="Pediatric" post="Oncology, Hematology and Transplantology, University of Medical SciencesPoznanPoland[4], Department"/>
 <result pre="Oncology, Hematology and Transplantology, University of Medical SciencesPoznanPoland[4], Department of" exact="Pediatric" post="Hematology, Oncology and Stem Cell Transplantation, Medical UniversityLublinPoland[5], Stem"/>
 <result pre="Clinical Immunology and Transplantology, Jagiellonian University Collegium MedicumKrakowPoland[6], Department of" exact="General" post="and Oncological Surgery for Children and Adolescents, Collegium Medicum,"/>
 <result pre="Medicum, Nicolaus Copernicus University TorunBydgoszczPoland Correspondence: Krzysztof Czyzewski Department of" exact="Pediatric" post="Hematology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus"/>
 <result pre="Objective The analysis of epidemiology, risk factors and outcome of" exact="viral" post="infections in children and adolescents after hematopoietic cell transplantation"/>
 <result pre="The analysis of epidemiology, risk factors and outcome of viral" exact="infections" post="in children and adolescents after hematopoietic cell transplantation (HCT)."/>
 <result pre="cell transplantation (HCT). Methods In this multicenter nationwide study a" exact="total" post="of 971 HCT procedures (741 allo-HCT; 230 auto-HCT) over"/>
 <result pre="years were analyzed. Results During this period 801 episodes of" exact="viral" post="infections were diagnosed in 442 patients. The incidence of"/>
 <result pre="were analyzed. Results During this period 801 episodes of viral" exact="infections" post="were diagnosed in 442 patients. The incidence of viral"/>
 <result pre="viral infections were diagnosed in 442 patients. The incidence of" exact="viral" post="infections was 57.9% in allo-HCT and 4.8% in auto-HCT"/>
 <result pre="infections were diagnosed in 442 patients. The incidence of viral" exact="infections" post="was 57.9% in allo-HCT and 4.8% in auto-HCT patients."/>
 <result pre="in allo-HCT and 4.8% in auto-HCT patients. The most frequent" exact="infections" post="after allo-HCT were caused by cytomegalovirus (CMV), polyoma BK"/>
 <result pre="BK virus (BKV) and Epstein–Barr virus (EBV). The majority of" exact="infections" post="occurred within the first 4 months after allo-HCT and"/>
 <result pre="4 months after allo-HCT and over 80% required pharmacotherapy or" exact="symptomatic" post="therapy. The median time of treatment of specific viral"/>
 <result pre="or symptomatic therapy. The median time of treatment of specific" exact="viral infection" post="ranged from 7 (for EBV) to 24 (for CMV)"/>
 <result pre="symptomatic therapy. The median time of treatment of specific viral" exact="infection" post="ranged from 7 (for EBV) to 24 (for CMV)"/>
 <result pre="observed in case of CMV infection. The risk factors for" exact="viral" post="infections were allo-HCT, acute leukemia, acute and chronic graft"/>
 <result pre="in case of CMV infection. The risk factors for viral" exact="infections" post="were allo-HCT, acute leukemia, acute and chronic graft versus"/>
 <result pre="CMV infection. The risk factors for viral infections were allo-HCT," exact="acute" post="leukemia, acute and chronic graft versus host disease (a/cGVHD),"/>
 <result pre="The risk factors for viral infections were allo-HCT, acute leukemia," exact="acute" post="and chronic graft versus host disease (a/cGVHD), and matched"/>
 <result pre="factors for viral infections were allo-HCT, acute leukemia, acute and" exact="chronic" post="graft versus host disease (a/cGVHD), and matched unrelated donor"/>
 <result pre="were allo-HCT, acute leukemia, acute and chronic graft versus host" exact="disease" post="(a/cGVHD), and matched unrelated donor (MUD)/mismatched unrelated donor (MMUD)-HCT."/>
 <result pre="(MUD)/mismatched unrelated donor (MMUD)-HCT. The risk factor for death from" exact="viral infection" post="were CMV-IgG seropositivity in acute lymphoblastic leukemia recipient, and"/>
 <result pre="unrelated donor (MMUD)-HCT. The risk factor for death from viral" exact="infection" post="were CMV-IgG seropositivity in acute lymphoblastic leukemia recipient, and"/>
 <result pre="factor for death from viral infection were CMV-IgG seropositivity in" exact="acute lymphoblastic leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
 <result pre="for death from viral infection were CMV-IgG seropositivity in acute" exact="lymphoblastic leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
 <result pre="death from viral infection were CMV-IgG seropositivity in acute lymphoblastic" exact="leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
 <result pre="acute lymphoblastic leukemia recipient, and MUD/MMUD-HCT. The incidence of EBV" exact="infection" post="requiring pre-emptive treatment with rituximab in allo-HCT children was"/>
 <result pre="cases of EBV infection, these episodes were preceded by other" exact="viral infection" post="and treated with antivirals, which did not prevent development"/>
 <result pre="of EBV infection, these episodes were preceded by other viral" exact="infection" post="and treated with antivirals, which did not prevent development"/>
 <result pre="EBV reactivation in allo-HCT pediatric patients. Keywords children EBV HCT" exact="infectious" post="complications risk factors analysis viral infections fig-count: table-count: ref-count:"/>
 <result pre="patients. Keywords children EBV HCT infectious complications risk factors analysis" exact="viral" post="infections fig-count: table-count: ref-count: page-count: Introduction Infections are the"/>
 <result pre="Keywords children EBV HCT infectious complications risk factors analysis viral" exact="infections" post="fig-count: table-count: ref-count: page-count: Introduction Infections are the major"/>
 <result pre="risk factors analysis viral infections fig-count: table-count: ref-count: page-count: Introduction" exact="Infections" post="are the major cause of mobility and mortality in"/>
 <result pre="chemotherapy due to malignancy.1–3 According to the Center for International" exact="Blood" post="and Marrow Transplant Research (CIBMTR), infectious complications were the"/>
 <result pre="the Center for International Blood and Marrow Transplant Research (CIBMTR)," exact="infectious" post="complications were the cause of death in 7% of"/>
 <result pre="(MSD-HCT) and 13% of matched unrelated donor HCT (MUD-HCT) recipients.2" exact="Infectious" post="complications in children after HCT were noted in 82%"/>
 <result pre="allogeneic HCT (allo-HCT)4 and in 21% of children with solid" exact="tumor" post="or lymphoma in pediatric auto-HCT setting.5 The incidence of"/>
 <result pre="(allo-HCT)4 and in 21% of children with solid tumor or" exact="lymphoma" post="in pediatric auto-HCT setting.5 The incidence of viral infection"/>
 <result pre="tumor or lymphoma in pediatric auto-HCT setting.5 The incidence of" exact="viral infection" post="after allo-HCT was observed in 19.3% of patients during"/>
 <result pre="or lymphoma in pediatric auto-HCT setting.5 The incidence of viral" exact="infection" post="after allo-HCT was observed in 19.3% of patients during"/>
 <result pre="up to 2 years after HCT.4 In the auto-HCT setting" exact="viral" post="infections were observed only in 11% of patients with"/>
 <result pre="to 2 years after HCT.4 In the auto-HCT setting viral" exact="infections" post="were observed only in 11% of patients with median"/>
 <result pre="with median onset of 10 days post-transplant.5 Viruses that cause" exact="infection" post="after HCT can be classified as latent or &quot;episodic&quot;"/>
 <result pre="classified as latent or &quot;episodic&quot; in nature, with the latter" exact="acquired" post="typically after exposure rather than as a result of"/>
 <result pre="result of a reactivation event.6 In the early post-transplant period" exact="herpes" post="simplex virus (HSV) reactivation was the most frequent viral"/>
 <result pre="period herpes simplex virus (HSV) reactivation was the most frequent" exact="viral infection" post="both in allo-HCT and auto-HCT patients.4,5 Overall, 8% of"/>
 <result pre="herpes simplex virus (HSV) reactivation was the most frequent viral" exact="infection" post="both in allo-HCT and auto-HCT patients.4,5 Overall, 8% of"/>
 <result pre="patients.4,5 Overall, 8% of allo-HCT patient died primarily due to" exact="infections" post="and 24% of these infections were viral.4 In auto-HCT"/>
 <result pre="patient died primarily due to infections and 24% of these" exact="infections" post="were viral.4 In auto-HCT patients deaths due to infections"/>
 <result pre="these infections were viral.4 In auto-HCT patients deaths due to" exact="infections" post="were episodic.5 Some major improvements in outcomes were associated"/>
 <result pre="of drugs and molecular tests to detect and prevent early" exact="bacterial infections," post="HSV, cytomegalovirus (CMV), and pre-engraftment candidal infections.6 Screening for"/>
 <result pre="with rituximab, has reduced the incidence of mortality from post-transplant" exact="lymphoproliferative disease" post="(EBV-PTLD) from 84% before the year 2000 to 30%"/>
 <result pre="rituximab, has reduced the incidence of mortality from post-transplant lymphoproliferative" exact="disease" post="(EBV-PTLD) from 84% before the year 2000 to 30%"/>
 <result pre="present analysis of the epidemiology, risk factors and outcome of" exact="viral" post="infections in children and adolescents after HCT over a"/>
 <result pre="analysis of the epidemiology, risk factors and outcome of viral" exact="infections" post="in children and adolescents after HCT over a period"/>
 <result pre="was given to antiviral drugs usage and incidence of EBV" exact="infection" post="after HCT. Materials and Methods Design of the Study"/>
 <result pre="cohort analysis performed on behalf of the Polish Society of" exact="Pediatric" post="Oncology and Hematology. Viral infections diagnosed during a six-year"/>
 <result pre="behalf of the Polish Society of Pediatric Oncology and Hematology." exact="Viral" post="infections diagnosed during a six-year period (between January 1,"/>
 <result pre="of the Polish Society of Pediatric Oncology and Hematology. Viral" exact="infections" post="diagnosed during a six-year period (between January 1, 2012"/>
 <result pre="2-year period were collected retrospectively, then prospectively afterwards. Pathogen Diagnosis" exact="Viral" post="infections were classified as episodic (diagnosed on the basis"/>
 <result pre="period were collected retrospectively, then prospectively afterwards. Pathogen Diagnosis Viral" exact="infections" post="were classified as episodic (diagnosed on the basis of"/>
 <result pre="A and B (FLUAV and FLUBV, respectively) and other community-acquired" exact="respiratory" post="viruses (CARV), such as parainfluenza (HPIV), human metapneumovirus (hMPV),"/>
 <result pre="respiratory viruses (CARV), such as parainfluenza (HPIV), human metapneumovirus (hMPV)," exact="respiratory" post="syncytial virus (RSV), rhinovirus (RhV), as well as parvovirus"/>
 <result pre="chain reaction (PCR)-based analysis was used for the diagnosis of" exact="viral" post="infections of material derived from blood, urine, cerebrospinal fluid,"/>
 <result pre="reaction (PCR)-based analysis was used for the diagnosis of viral" exact="infections" post="of material derived from blood, urine, cerebrospinal fluid, respiratory"/>
 <result pre="viral infections of material derived from blood, urine, cerebrospinal fluid," exact="respiratory" post="swabs or bronchoalveolar lavage. According to recommendations of the"/>
 <result pre="bronchoalveolar lavage. According to recommendations of the European Conference on" exact="Infections" post="in Leukaemia (ECIL), a pre-emptive quantitative approach was introduced"/>
 <result pre="in Leukaemia (ECIL), a pre-emptive quantitative approach was introduced for" exact="infections" post="with CMV and EBV in allo-HCT patients.8,9 Recurrent viral"/>
 <result pre="introduced for infections with CMV and EBV in allo-HCT patients.8,9" exact="Recurrent" post="viral infection was defined as a new episode of"/>
 <result pre="for infections with CMV and EBV in allo-HCT patients.8,9 Recurrent" exact="viral infection" post="was defined as a new episode of viral infection"/>
 <result pre="infections with CMV and EBV in allo-HCT patients.8,9 Recurrent viral" exact="infection" post="was defined as a new episode of viral infection"/>
 <result pre="Recurrent viral infection was defined as a new episode of" exact="viral infection" post="in a patient with previous evidence of the same"/>
 <result pre="viral infection was defined as a new episode of viral" exact="infection" post="in a patient with previous evidence of the same"/>
 <result pre="infection in a patient with previous evidence of the same" exact="viral infection" post="in whom the virus has not been detected for"/>
 <result pre="in a patient with previous evidence of the same viral" exact="infection" post="in whom the virus has not been detected for"/>
 <result pre="been detected for at least 4 weeks during active surveillance." exact="Recurrent" post="infection could have resulted from reactivation of latent virus"/>
 <result pre="detected for at least 4 weeks during active surveillance. Recurrent" exact="infection" post="could have resulted from reactivation of latent virus or"/>
 <result pre="have resulted from reactivation of latent virus or exogenous reinfection.10" exact="Multiple" post="viral infections were defined as infections with two or"/>
 <result pre="resulted from reactivation of latent virus or exogenous reinfection.10 Multiple" exact="viral" post="infections were defined as infections with two or more"/>
 <result pre="from reactivation of latent virus or exogenous reinfection.10 Multiple viral" exact="infections" post="were defined as infections with two or more viruses"/>
 <result pre="virus or exogenous reinfection.10 Multiple viral infections were defined as" exact="infections" post="with two or more viruses in one patient in"/>
 <result pre="event was defined as the diagnosis of a first specific" exact="infectious" post="disorder. Categorical variables were compared by the chi-square test,"/>
 <result pre="intervals (CI) were calculated for the difference in occurrence of" exact="infections" post="in patients. Cumulative incidences of viral infections were calculated"/>
 <result pre="difference in occurrence of infections in patients. Cumulative incidences of" exact="viral" post="infections were calculated using competing risk analysis,13 starting from"/>
 <result pre="in occurrence of infections in patients. Cumulative incidences of viral" exact="infections" post="were calculated using competing risk analysis,13 starting from the"/>
 <result pre="Demographics Over the analysis period of 72 consecutive months, a" exact="total" post="of 971 HCT (741 allo-HCT; 230 auto-HCT) were performed."/>
 <result pre="(741 allo-HCT; 230 auto-HCT) were performed. Indications for HCTs were:" exact="acute lymphoblastic leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
 <result pre="allo-HCT; 230 auto-HCT) were performed. Indications for HCTs were: acute" exact="lymphoblastic leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
 <result pre="230 auto-HCT) were performed. Indications for HCTs were: acute lymphoblastic" exact="leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
 <result pre="performed. Indications for HCTs were: acute lymphoblastic leukemia (ALL, n=233)," exact="acute" post="myeloblastic leukemia (AML, n=151), neuroblastoma (n=138), primary immunodeficiencies (n=113),"/>
 <result pre="for HCTs were: acute lymphoblastic leukemia (ALL, n=233), acute myeloblastic" exact="leukemia" post="(AML, n=151), neuroblastoma (n=138), primary immunodeficiencies (n=113), bone marrow"/>
 <result pre="acute lymphoblastic leukemia (ALL, n=233), acute myeloblastic leukemia (AML, n=151)," exact="neuroblastoma" post="(n=138), primary immunodeficiencies (n=113), bone marrow failure syndromes (n=101),"/>
 <result pre="leukemia (ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138)," exact="primary" post="immunodeficiencies (n=113), bone marrow failure syndromes (n=101), Non-Hodgkin Lymphoma"/>
 <result pre="neuroblastoma (n=138), primary immunodeficiencies (n=113), bone marrow failure syndromes (n=101)," exact="Non-Hodgkin Lymphoma" post="and Hodgkin Lymphoma (NHL/HD, n=65), Ewing sarcoma (n=44), myelodysplastic"/>
 <result pre="(n=138), primary immunodeficiencies (n=113), bone marrow failure syndromes (n=101), Non-Hodgkin" exact="Lymphoma" post="and Hodgkin Lymphoma (NHL/HD, n=65), Ewing sarcoma (n=44), myelodysplastic"/>
 <result pre="(n=113), bone marrow failure syndromes (n=101), Non-Hodgkin Lymphoma and Hodgkin" exact="Lymphoma" post="(NHL/HD, n=65), Ewing sarcoma (n=44), myelodysplastic syndrome (n=38) and"/>
 <result pre="failure syndromes (n=101), Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65)," exact="Ewing sarcoma" post="(n=44), myelodysplastic syndrome (n=38) and other indications (n=88). Incidence"/>
 <result pre="syndromes (n=101), Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65), Ewing" exact="sarcoma" post="(n=44), myelodysplastic syndrome (n=38) and other indications (n=88). Incidence"/>
 <result pre="Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65), Ewing sarcoma (n=44)," exact="myelodysplastic syndrome" post="(n=38) and other indications (n=88). Incidence of Infection A"/>
 <result pre="Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65), Ewing sarcoma (n=44), myelodysplastic" exact="syndrome" post="(n=38) and other indications (n=88). Incidence of Infection A"/>
 <result pre="(n=44), myelodysplastic syndrome (n=38) and other indications (n=88). Incidence of" exact="Infection" post="A total of 801 episodes of viral infections were"/>
 <result pre="syndrome (n=38) and other indications (n=88). Incidence of Infection A" exact="total" post="of 801 episodes of viral infections were diagnosed in"/>
 <result pre="(n=88). Incidence of Infection A total of 801 episodes of" exact="viral" post="infections were diagnosed in 442 patients (431 allo-HCT and"/>
 <result pre="Incidence of Infection A total of 801 episodes of viral" exact="infections" post="were diagnosed in 442 patients (431 allo-HCT and 11"/>
 <result pre="in 442 patients (431 allo-HCT and 11 auto-HCT). Overall, 788" exact="infections" post="(726 primary infections and 62 reinfections) (Table 1) were"/>
 <result pre="patients (431 allo-HCT and 11 auto-HCT). Overall, 788 infections (726" exact="primary" post="infections and 62 reinfections) (Table 1) were diagnosed in"/>
 <result pre="(431 allo-HCT and 11 auto-HCT). Overall, 788 infections (726 primary" exact="infections" post="and 62 reinfections) (Table 1) were diagnosed in allo-HCT,"/>
 <result pre="reinfections) (Table 1) were diagnosed in allo-HCT, and 13 (11" exact="primary" post="infections and 2 recurrent infections) in auto-HCT patients (Supplementary"/>
 <result pre="(Table 1) were diagnosed in allo-HCT, and 13 (11 primary" exact="infections" post="and 2 recurrent infections) in auto-HCT patients (Supplementary Table"/>
 <result pre="diagnosed in allo-HCT, and 13 (11 primary infections and 2" exact="recurrent" post="infections) in auto-HCT patients (Supplementary Table 1). Table 1"/>
 <result pre="in auto-HCT patients (Supplementary Table 1). Table 1 Specification of" exact="Viral Infection" post="and Therapy in Allo-HCT Setting Number of Infectious Episodes"/>
 <result pre="auto-HCT patients (Supplementary Table 1). Table 1 Specification of Viral" exact="Infection" post="and Therapy in Allo-HCT Setting Number of Infectious Episodes"/>
 <result pre="of Viral Infection and Therapy in Allo-HCT Setting Number of" exact="Infectious" post="Episodes Number of Primary Infections Number of Relapsed Infections"/>
 <result pre="Therapy in Allo-HCT Setting Number of Infectious Episodes Number of" exact="Primary" post="Infections Number of Relapsed Infections Symptomatic Therapy Number of"/>
 <result pre="in Allo-HCT Setting Number of Infectious Episodes Number of Primary" exact="Infections" post="Number of Relapsed Infections Symptomatic Therapy Number of Therapies"/>
 <result pre="of Infectious Episodes Number of Primary Infections Number of Relapsed" exact="Infections" post="Symptomatic Therapy Number of Therapies Pharmacotherapy Survival (%) CMV*"/>
 <result pre="T lymphocytes; EBV, Epstein–Barr virus; FLUAV, influenza A virus; HBV," exact="hepatitis" post="B virus; HHV-6, human herpesvirus 6; hMPV, human metapneumovirus;"/>
 <result pre="human immunoglobulins; NoV, norovirus; PVB19, parvovirus B19; RhV, rhinovirus; RSV," exact="respiratory" post="syncytial virus; RV, rotavirus; VZIG, varicella-zoster human immune globulin;"/>
 <result pre="human immune globulin; VZV, varicella-zoster virus. The cumulative incidence of" exact="viral" post="infections was 57.9% (95% CI=56.1–59.7) in allo-HCT patients, and"/>
 <result pre="immune globulin; VZV, varicella-zoster virus. The cumulative incidence of viral" exact="infections" post="was 57.9% (95% CI=56.1–59.7) in allo-HCT patients, and 4.8%"/>
 <result pre="CI=3.4–6.2) (p&amp;lt;0.001) (Figure 1A). Due to the small number of" exact="infections" post="in the auto-HCT setting, these data were excluded from"/>
 <result pre="Supplementary Table 1. Figure 1 (A). The cumulative incidence of" exact="viral" post="infections in allo-HCT and auto-HCT patients. (B). The cumulative"/>
 <result pre="Table 1. Figure 1 (A). The cumulative incidence of viral" exact="infections" post="in allo-HCT and auto-HCT patients. (B). The cumulative incidence"/>
 <result pre="auto-HCT patients. (B). The cumulative incidence of four most frequent" exact="viral" post="infections in allo-HCT setting. In the allo-HCT setting, viral"/>
 <result pre="patients. (B). The cumulative incidence of four most frequent viral" exact="infections" post="in allo-HCT setting. In the allo-HCT setting, viral infection"/>
 <result pre="frequent viral infections in allo-HCT setting. In the allo-HCT setting," exact="viral infection" post="with a single pathogen occurred in 54.0% of patients,"/>
 <result pre="viral infections in allo-HCT setting. In the allo-HCT setting, viral" exact="infection" post="with a single pathogen occurred in 54.0% of patients,"/>
 <result pre="pathogen occurred in 54.0% of patients, while there were multiple" exact="viral" post="infections in 46.0% of patients (29.0% with two viruses,"/>
 <result pre="occurred in 54.0% of patients, while there were multiple viral" exact="infections" post="in 46.0% of patients (29.0% with two viruses, 13.7%"/>
 <result pre="viruses and 0.7% with five viruses). The cumulative incidence of" exact="viral" post="infections was 28.9% for CMV, 23.8% for BKV, 22.7%"/>
 <result pre="and 0.7% with five viruses). The cumulative incidence of viral" exact="infections" post="was 28.9% for CMV, 23.8% for BKV, 22.7% for"/>
 <result pre="0.1% for HBV. The incidence of CMV, BKV and EBV" exact="infections" post="were significantly higher than ADV (p&amp;lt;0.001) and other viral"/>
 <result pre="EBV infections were significantly higher than ADV (p&amp;lt;0.001) and other" exact="viral" post="infections. The cumulative incidence of four most frequent viral"/>
 <result pre="other viral infections. The cumulative incidence of four most frequent" exact="viral" post="infections is shown in Figure 1B. Most of the"/>
 <result pre="viral infections. The cumulative incidence of four most frequent viral" exact="infections" post="is shown in Figure 1B. Most of the viral"/>
 <result pre="viral infections is shown in Figure 1B. Most of the" exact="viral" post="infections occurred within the first 4 months from allo-HCT."/>
 <result pre="infections is shown in Figure 1B. Most of the viral" exact="infections" post="occurred within the first 4 months from allo-HCT. There"/>
 <result pre="median patient age and median time from allo-HCT to specific" exact="viral infection," post="with respective values ranging from 0.4 to 3.8 months."/>
 <result pre="Only in cases of VZV, HSV and NoV were late" exact="infections" post="observed, with a median time 6.5, 7.4 and 7.9"/>
 <result pre="7.9 months, respectively (Supplementary Table 2). Treatment Of 788 specific" exact="viral" post="infections (726 primary infections and 62 recurrent infections) in"/>
 <result pre="months, respectively (Supplementary Table 2). Treatment Of 788 specific viral" exact="infections" post="(726 primary infections and 62 recurrent infections) in 631"/>
 <result pre="(Supplementary Table 2). Treatment Of 788 specific viral infections (726" exact="primary" post="infections and 62 recurrent infections) in 631 (80.1%) episodes"/>
 <result pre="Table 2). Treatment Of 788 specific viral infections (726 primary" exact="infections" post="and 62 recurrent infections) in 631 (80.1%) episodes therapies"/>
 <result pre="Of 788 specific viral infections (726 primary infections and 62" exact="recurrent" post="infections) in 631 (80.1%) episodes therapies were performed: 583"/>
 <result pre="episodes therapies were performed: 583 (92.4%) pharmacotherapies and 48 (7.6%)" exact="symptomatic" post="therapies. In all episodes of HHV-6, VZV, HPIV, HSV,"/>
 <result pre="CMV, 92.6% FLUAV, 81.7% EBV, 60.0% ADV and 53.0% BKV" exact="infectious" post="episodes specific antiviral pharmacotherapy was used. No specific pharmacotherapy"/>
 <result pre="for RV, RhV, NoV, PVB19 and HBV. The most frequent" exact="symptomatic" post="therapies were used in RV (19/48), ADV (10/48), BKV"/>
 <result pre="therapies were used in RV (19/48), ADV (10/48), BKV (5/48)" exact="infections" post="(Table 1). The median time of treatment of specific"/>
 <result pre="infections (Table 1). The median time of treatment of specific" exact="viral infection" post="range from 7 days for EBV, RV, FLUAV, RhV,"/>
 <result pre="(Table 1). The median time of treatment of specific viral" exact="infection" post="range from 7 days for EBV, RV, FLUAV, RhV,"/>
 <result pre="to 22.5 days for BKV and 24 days for CMV" exact="infections" post="(Supplementary Table 2). Survival After Infections There were no"/>
 <result pre="24 days for CMV infections (Supplementary Table 2). Survival After" exact="Infections" post="There were no deaths related to RV, HHV-6, VZV,"/>
 <result pre="RSV, RhV, NoV, HSV, hMPV, and PVB19 infection. For episodic" exact="viral" post="infections one death was related to FLUAV (survival 92.9%)"/>
 <result pre="RhV, NoV, HSV, hMPV, and PVB19 infection. For episodic viral" exact="infections" post="one death was related to FLUAV (survival 92.9%) and"/>
 <result pre="one to HPIV (survival 66.7%). For the four most frequent" exact="viral" post="infections (CMV, BKV, EBV and ADV) survival rate ranged"/>
 <result pre="to HPIV (survival 66.7%). For the four most frequent viral" exact="infections" post="(CMV, BKV, EBV and ADV) survival rate ranged between"/>
 <result pre="EBV and ADV) survival rate ranged between 90.3% for ADV" exact="infection" post="and 95.4 for EBV infection and did not differ"/>
 <result pre="ranged between 90.3% for ADV infection and 95.4 for EBV" exact="infection" post="and did not differ between specific viral infection (p=0.3)"/>
 <result pre="95.4 for EBV infection and did not differ between specific" exact="viral infection" post="(p=0.3) (Figure 2A). With respect to primary diagnosis, survival"/>
 <result pre="for EBV infection and did not differ between specific viral" exact="infection" post="(p=0.3) (Figure 2A). With respect to primary diagnosis, survival"/>
 <result pre="between specific viral infection (p=0.3) (Figure 2A). With respect to" exact="primary" post="diagnosis, survival from viral infection was 97.4% (95% CI=95.9–98.9)"/>
 <result pre="(p=0.3) (Figure 2A). With respect to primary diagnosis, survival from" exact="viral infection" post="was 97.4% (95% CI=95.9–98.9) in AML and 92.4% (95%"/>
 <result pre="(Figure 2A). With respect to primary diagnosis, survival from viral" exact="infection" post="was 97.4% (95% CI=95.9–98.9) in AML and 92.4% (95%"/>
 <result pre="statistically differ between these two (p=0.073) (Figure 2B) and other" exact="primary" post="diseases. Figure 2 (A). Survival from four most frequent"/>
 <result pre="primary diseases. Figure 2 (A). Survival from four most frequent" exact="viral" post="infections in allo-HCT setting. (B). Survival from viral infections"/>
 <result pre="diseases. Figure 2 (A). Survival from four most frequent viral" exact="infections" post="in allo-HCT setting. (B). Survival from viral infections in"/>
 <result pre="most frequent viral infections in allo-HCT setting. (B). Survival from" exact="viral" post="infections in AML and ALL patients. Risk Factor Analysis"/>
 <result pre="frequent viral infections in allo-HCT setting. (B). Survival from viral" exact="infections" post="in AML and ALL patients. Risk Factor Analysis Risk"/>
 <result pre="AML and ALL patients. Risk Factor Analysis Risk Factors for" exact="Viral" post="Infections In multivariate analysis, the risk of infections was"/>
 <result pre="and ALL patients. Risk Factor Analysis Risk Factors for Viral" exact="Infections" post="In multivariate analysis, the risk of infections was higher"/>
 <result pre="Factors for Viral Infections In multivariate analysis, the risk of" exact="infections" post="was higher after allo-HCT (HR=18.0; p&amp;lt;0.001) than auto-HCT. In"/>
 <result pre="than auto-HCT. In allo-HCT patients, the risk was higher in" exact="acute" post="leukemia patients vs other (HR=1.9; p&amp;lt;0.001), MUD vs MSD"/>
 <result pre="auto-HCT. In allo-HCT patients, the risk was higher in acute" exact="leukemia" post="patients vs other (HR=1.9; p&amp;lt;0.001), MUD vs MSD (HR=2.6;"/>
 <result pre="(HR=2.6; p&amp;lt;0.001), MMUD (mismatched unrelated donor) vs MSD (HR=4.2; p&amp;lt;0.001)," exact="acute" post="and chronic graft versus host disease (a/cGVHD) before infection"/>
 <result pre="MMUD (mismatched unrelated donor) vs MSD (HR=4.2; p&amp;lt;0.001), acute and" exact="chronic" post="graft versus host disease (a/cGVHD) before infection (HR=1.9; p&amp;lt;0.001"/>
 <result pre="vs MSD (HR=4.2; p&amp;lt;0.001), acute and chronic graft versus host" exact="disease" post="(a/cGVHD) before infection (HR=1.9; p&amp;lt;0.001 and HR=3.4; p&amp;lt;0.001, respectively)"/>
 <result pre="p&amp;lt;0.001), acute and chronic graft versus host disease (a/cGVHD) before" exact="infection" post="(HR=1.9; p&amp;lt;0.001 and HR=3.4; p&amp;lt;0.001, respectively) (Table 2). Table"/>
 <result pre="(Table 2). Table 2 Multivariate Analysis of Risk Factors for" exact="Viral Infection" post="Risk Factor HR (95%CI) p Allo- vs auto-HCT 18.0"/>
 <result pre="2). Table 2 Multivariate Analysis of Risk Factors for Viral" exact="Infection" post="Risk Factor HR (95%CI) p Allo- vs auto-HCT 18.0"/>
 <result pre="Allo- vs auto-HCT 18.0 (13–22) &amp;lt;0.001 allo-HCT Sex male vs" exact="female" post="0.9 (0.7–1.1) 0.698 Acute leukemia vs other 1.9 (1.4–2.4)"/>
 <result pre="(13–22) &amp;lt;0.001 allo-HCT Sex male vs female 0.9 (0.7–1.1) 0.698" exact="Acute" post="leukemia vs other 1.9 (1.4–2.4) &amp;lt;0.001 NHL/HD vs other"/>
 <result pre="&amp;lt;0.001 allo-HCT Sex male vs female 0.9 (0.7–1.1) 0.698 Acute" exact="leukemia" post="vs other 1.9 (1.4–2.4) &amp;lt;0.001 NHL/HD vs other 1.2"/>
 <result pre="bold font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; D, days;"/>
 <result pre="font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; D, days;"/>
 <result pre="BM, bone marrow; D, days; HCT, hematopoietic cell transplantation; HD," exact="Hodgkin lymphoma;" post="MAC, myeloablative conditioning; MMUD, mismatched unrelated donor; MUD, matched"/>
 <result pre="sibling donor; NHL, Non-Hodgkin lymphoma; RIC, reduced-intensity of conditioning; PB," exact="peripheral" post="blood; TBI, total body irradiation. Risk Factor for Death"/>
 <result pre="Non-Hodgkin lymphoma; RIC, reduced-intensity of conditioning; PB, peripheral blood; TBI," exact="total" post="body irradiation. Risk Factor for Death from Viral Infection"/>
 <result pre="blood; TBI, total body irradiation. Risk Factor for Death from" exact="Viral Infection" post="After HCT Among auto-HCT patients, no child died of"/>
 <result pre="TBI, total body irradiation. Risk Factor for Death from Viral" exact="Infection" post="After HCT Among auto-HCT patients, no child died of"/>
 <result pre="Infection After HCT Among auto-HCT patients, no child died of" exact="viral infection." post="For allo-HCT patients, a CMV-IgG positive recipient with ALL"/>
 <result pre="For allo-HCT patients, a CMV-IgG positive recipient with ALL as" exact="primary" post="disease was a risk factor for death (HR=1.5; p=0.045)"/>
 <result pre="allo-HCT patients, a CMV-IgG positive recipient with ALL as primary" exact="disease" post="was a risk factor for death (HR=1.5; p=0.045) in"/>
 <result pre="Multivariate Logistic Regression Analysis for Risk Factors for Death from" exact="Viral Infection" post="After HCT Risk Factor HR (95%CI) p CMV-IgG+ in"/>
 <result pre="Logistic Regression Analysis for Risk Factors for Death from Viral" exact="Infection" post="After HCT Risk Factor HR (95%CI) p CMV-IgG+ in"/>
 <result pre="in recipient and ALL 1.5 (1.1–2.0) 0.045 Sex male vs" exact="female" post="1.1 (0.8–1.5) 0.829 Acute leukemia vs other 1.5 (0.8–2.4)"/>
 <result pre="1.5 (1.1–2.0) 0.045 Sex male vs female 1.1 (0.8–1.5) 0.829" exact="Acute" post="leukemia vs other 1.5 (0.8–2.4) 0.413 NHL/HD vs other"/>
 <result pre="(1.1–2.0) 0.045 Sex male vs female 1.1 (0.8–1.5) 0.829 Acute" exact="leukemia" post="vs other 1.5 (0.8–2.4) 0.413 NHL/HD vs other 0.9"/>
 <result pre="bold font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; CMV, cytomegalovirus;"/>
 <result pre="font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; CMV, cytomegalovirus;"/>
 <result pre="marrow; CMV, cytomegalovirus; D, days; HCT, hematopoietic cell transplantation; HD," exact="Hodgkin lymphoma;" post="HR, hazard ratio; MAC, myeloablative conditioning; MMUD, mismatched unrelated"/>
 <result pre="sibling donor; MUD, matched unrelated donor; NHL, Non-Hodgkin lymphoma; PB," exact="peripheral" post="blood; RIC, reduced-intensity of conditioning; TBI, total body irradiation."/>
 <result pre="Non-Hodgkin lymphoma; PB, peripheral blood; RIC, reduced-intensity of conditioning; TBI," exact="total" post="body irradiation. Viral Infections Preceding EBV Infection In order"/>
 <result pre="peripheral blood; RIC, reduced-intensity of conditioning; TBI, total body irradiation." exact="Viral" post="Infections Preceding EBV Infection In order to assess the"/>
 <result pre="blood; RIC, reduced-intensity of conditioning; TBI, total body irradiation. Viral" exact="Infections" post="Preceding EBV Infection In order to assess the impact"/>
 <result pre="reduced-intensity of conditioning; TBI, total body irradiation. Viral Infections Preceding" exact="EBV Infection" post="In order to assess the impact of antivirals on"/>
 <result pre="of conditioning; TBI, total body irradiation. Viral Infections Preceding EBV" exact="Infection" post="In order to assess the impact of antivirals on"/>
 <result pre="days before the onset of significant EBV-DNA-emia. Of 175 EBV" exact="infectious" post="episodes, in 66 (37.7%) cases, the infection was preceded"/>
 <result pre="Of 175 EBV infectious episodes, in 66 (37.7%) cases, the" exact="infection" post="was preceded by another viral infection, including CMV (n=21),"/>
 <result pre="in 66 (37.7%) cases, the infection was preceded by another" exact="viral infection," post="including CMV (n=21), BKV (n=20), ADV (n=4), RV (n=3),"/>
 <result pre="FLUAV (n=1), HPIV (n=1), RSV (n=1), VZV (n=1), or multiple" exact="infections" post="(BKV+CMV, n=8; BKV+RV, n=3; ADV+CMV, n=1; ADV+HHV6, n=1; ADV+RV,"/>
 <result pre="with rituximab was required. In 44/54 (81.5%) of these cases" exact="viral" post="infections preceding EBV infection were treated with antiviral drugs,"/>
 <result pre="rituximab was required. In 44/54 (81.5%) of these cases viral" exact="infections" post="preceding EBV infection were treated with antiviral drugs, including:"/>
 <result pre="In 44/54 (81.5%) of these cases viral infections preceding EBV" exact="infection" post="were treated with antiviral drugs, including: CDV (n=18), GCV"/>
 <result pre="BKV (n=11), ADV (n=4), FLUAV (n=1), VZV (n=1) or multiple" exact="infections" post="(BKV+CMV, n=7; BKV+RV, n=1; ADV+CMV, n=1; ADV+HHV-6, n=1; ADV+RV,"/>
 <result pre="ACV therapies and 1/13 (7.7%) of oseltamivir therapies. Discussion The" exact="primary" post="causes of morbidity and non-relapse mortality following HCT are"/>
 <result pre="primary causes of morbidity and non-relapse mortality following HCT are" exact="acute" post="and chronic GVHD, organ dysfunction and infection.15 Changes in"/>
 <result pre="of morbidity and non-relapse mortality following HCT are acute and" exact="chronic" post="GVHD, organ dysfunction and infection.15 Changes in the transplantation"/>
 <result pre="of effective supportive care strategies have decreased the incidence of" exact="infectious" post="complications early after conditioning therapy for allo-HCT, but have"/>
 <result pre="have also prolonged the risks beyond day +100.6 These late" exact="infections" post="might be caused by all types of microorganisms; however,"/>
 <result pre="prevention strategies.6 There are only a few articles focused on" exact="viral" post="complications in children after HCT.4,5,16,17 Herein we reported the"/>
 <result pre="nationwide study of the epidemiology, risk factors and outcome of" exact="viral" post="infections in children and adolescents after HCT over a"/>
 <result pre="study of the epidemiology, risk factors and outcome of viral" exact="infections" post="in children and adolescents after HCT over a period"/>
 <result pre="comparable principles of supportive therapy. We shown high incidence of" exact="viral" post="infections in allo-HCT patients whereas in auto-HCT patients the"/>
 <result pre="principles of supportive therapy. We shown high incidence of viral" exact="infections" post="in allo-HCT patients whereas in auto-HCT patients the incidence"/>
 <result pre="We observed that CMV had the highest incidence from all" exact="viral" post="infections. CMV is one of the most difficult infections"/>
 <result pre="all viral infections. CMV is one of the most difficult" exact="infections" post="that occur after allo-HCT.18 The CMV serostatus of the"/>
 <result pre="treatment.18 Nevertheless, management of patients with resistant or refractory CMV" exact="infection" post="or CMV disease is a challenge. Combination therapy (ganciclovir"/>
 <result pre="of patients with resistant or refractory CMV infection or CMV" exact="disease" post="is a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir,"/>
 <result pre="reduced, if possible.18 We observed that cumulative incidence of BKV" exact="infection" post="was 23.8% with survival rate of 90.7%. Cesaro et"/>
 <result pre="survival rate of 90.7%. Cesaro et al. reported that BKV-related" exact="hemorrhagic cystitis" post="occurred in 8–25% of pediatric and 7–54% of adult"/>
 <result pre="rate of 90.7%. Cesaro et al. reported that BKV-related hemorrhagic" exact="cystitis" post="occurred in 8–25% of pediatric and 7–54% of adult"/>
 <result pre="hemorrhagic cystitis occurred in 8–25% of pediatric and 7–54% of" exact="adult" post="recipients undergoing allo-HCT.19 Specific anti-BKV prophylaxis is not available"/>
 <result pre="given the lack of significant effects on BKV replication and" exact="hemorrhagic cystitis" post="severity, and the selection of antibiotic resistance.19 In our"/>
 <result pre="the lack of significant effects on BKV replication and hemorrhagic" exact="cystitis" post="severity, and the selection of antibiotic resistance.19 In our"/>
 <result pre="were used by other authors for the treatment of BKV" exact="hemorrhagic cystitis," post="although without strong recommendation on its use in these"/>
 <result pre="its use in these doses.19 The clinical manifestations of ADV" exact="infections" post="in immunocompetent hosts include upper respiratory disease, gastroenteritis or"/>
 <result pre="The clinical manifestations of ADV infections in immunocompetent hosts include" exact="upper" post="respiratory disease, gastroenteritis or (kerato-)conjunctivitis and are self-limited in"/>
 <result pre="clinical manifestations of ADV infections in immunocompetent hosts include upper" exact="respiratory" post="disease, gastroenteritis or (kerato-)conjunctivitis and are self-limited in most"/>
 <result pre="of ADV infections in immunocompetent hosts include upper respiratory disease," exact="gastroenteritis" post="or (kerato-)conjunctivitis and are self-limited in most cases, although"/>
 <result pre="in most cases, although severe manifestations including encephalitis, myocarditis, and" exact="pneumonia" post="have been sporadically observed. In immunocompromised patients, ADV can"/>
 <result pre="have been sporadically observed. In immunocompromised patients, ADV can cause" exact="systemic" post="disease and lethal organ damage.20 Prophylactic antiviral therapy with"/>
 <result pre="been sporadically observed. In immunocompromised patients, ADV can cause systemic" exact="disease" post="and lethal organ damage.20 Prophylactic antiviral therapy with available"/>
 <result pre="(6–28% vs 0–6%, respectively);20 we observed 10.7% incidence of ADV" exact="infection" post="with 90.3% survival rate. A relatively low percentage of"/>
 <result pre="infection with 90.3% survival rate. A relatively low percentage of" exact="infections" post="with CARV origin was observed in our analysis. CARV"/>
 <result pre="infections with CARV origin was observed in our analysis. CARV" exact="respiratory" post="tract infections have been recognized as a significant cause"/>
 <result pre="CARV origin was observed in our analysis. CARV respiratory tract" exact="infections" post="have been recognized as a significant cause of morbidity"/>
 <result pre="a significant cause of morbidity and mortality in patients with" exact="leukemia" post="and those undergoing HCT.12,21 In the late 1990s the"/>
 <result pre="undergoing HCT.12,21 In the late 1990s the frequency of documented" exact="respiratory" post="virus infections was 3.5% among allo-HCT and 0.4% among"/>
 <result pre="In the late 1990s the frequency of documented respiratory virus" exact="infections" post="was 3.5% among allo-HCT and 0.4% among auto-HCT.22 However,"/>
 <result pre="allo-HCT and 0.4% among auto-HCT.22 However, in that time period," exact="viral" post="antigen detection by immunofluorescence or enzyme immunoassays were used"/>
 <result pre="the most recent multiplex PCR platform that can detect multiple" exact="viral" post="pathogens.21 Choi et al. reported in allo-HCT children the"/>
 <result pre="18% HPIV, 1.1% hMPV; yet more than half of the" exact="infections" post="were acquired during hospitalization.17 In the case of CARV"/>
 <result pre="1.1% hMPV; yet more than half of the infections were" exact="acquired" post="during hospitalization.17 In the case of CARV infections, ribavirin"/>
 <result pre="while there is insufficient evidence for the specific recommendation against" exact="infections" post="caused by coronavirus and RhV.12 We observed a relatively"/>
 <result pre="cases). The current guidelines of the 4th European Conference of" exact="Infections" post="in Leukemia (ECIL-4) recommend diagnosis based on PCR of"/>
 <result pre="current guidelines of the 4th European Conference of Infections in" exact="Leukemia" post="(ECIL-4) recommend diagnosis based on PCR of material collected"/>
 <result pre="recommend diagnosis based on PCR of material collected from the" exact="respiratory" post="tract, especially broncho-alveolar lavage.23 Neuraminidase inhibitors (oral oseltamivir or"/>
 <result pre="agents for influenza.23 RV and NoV are important pathogens of" exact="viral" post="gastroenteritis in children. We observed that cumulative incidence of"/>
 <result pre="for influenza.23 RV and NoV are important pathogens of viral" exact="gastroenteritis" post="in children. We observed that cumulative incidence of RV"/>
 <result pre="RV was 5% while NoV was 0.5%, treated only with" exact="symptomatic" post="therapy and no deaths were observed. In other studies"/>
 <result pre="deaths were observed. In other studies the incidence of RV" exact="infection" post="varied from 2.3% in adult allo-HCT and auto-HCT recipients"/>
 <result pre="studies the incidence of RV infection varied from 2.3% in" exact="adult" post="allo-HCT and auto-HCT recipients up to 19.6% in pediatric"/>
 <result pre="pediatric allo-HCT recipients.24,25 In pediatric HCT, the incidence of NoV-associated" exact="gastroenteritis" post="was reported in 12.9% with no NoV-related mortality.26 PCR"/>
 <result pre="and NoV infection. No specific prophylaxis against RV- and NoV-related" exact="gastroenterocolitis" post="is available; however, oral immunoglobulins and nitazoxanide were used"/>
 <result pre="and nitazoxanide were used in some studies.24,27 In immunocompetent individuals" exact="primary" post="EBV infection or reactivation induces usually asymptomatic infection or"/>
 <result pre="were used in some studies.24,27 In immunocompetent individuals primary EBV" exact="infection" post="or reactivation induces usually asymptomatic infection or infectious mononucleosis.28"/>
 <result pre="immunocompetent individuals primary EBV infection or reactivation induces usually asymptomatic" exact="infection" post="or infectious mononucleosis.28 In immunocompromised patients most EBV reactivations"/>
 <result pre="primary EBV infection or reactivation induces usually asymptomatic infection or" exact="infectious" post="mononucleosis.28 In immunocompromised patients most EBV reactivations are subclinical"/>
 <result pre="no therapy.8 However, it may be manifested as encephalitis/myelitis, pneumonia," exact="hepatitis" post="and EBV-associated tumors as PTLD.8,29 After transplantation 14–65% of"/>
 <result pre="of immunosuppressive regimens used.30 We observed high incidence of EBV" exact="infection" post="(22.7%) in allo-HCT patients, while there were no cases"/>
 <result pre="1/3 of EBV reactivations, these episodes were preceded by other" exact="viral infection" post="treated with antivirals, which did not prevent the development"/>
 <result pre="of EBV reactivations, these episodes were preceded by other viral" exact="infection" post="treated with antivirals, which did not prevent the development"/>
 <result pre="not active against EBV, presumably because of low levels of" exact="viral" post="thymidine kinase expression during lytic phase, and a lack"/>
 <result pre="be closely monitored for symptoms and/or signs attributable to EBV" exact="infection" post="and PTLD.8 The following pre-emptive therapies are recommended after"/>
 <result pre="response rate (50–88%) and fewer relapse.28 We found that allo-HCT," exact="acute" post="leukemia, a/cGVHD, MUD/MMUD-HCT were the risk factors for viral"/>
 <result pre="allo-HCT, acute leukemia, a/cGVHD, MUD/MMUD-HCT were the risk factors for" exact="viral" post="infections. CMV donor/recipient serostatus, era of transplantation, MUD-HCT, and"/>
 <result pre="cGVHD were found in other studies as risk factors for" exact="viral" post="infection.4 We have also found that CMV-IgG seropositivity in"/>
 <result pre="recipients, and MUD/MMUD-HCT were the risk factors for deaths from" exact="viral infection" post="in children after HCT. This is a unique observation,"/>
 <result pre="and MUD/MMUD-HCT were the risk factors for deaths from viral" exact="infection" post="in children after HCT. This is a unique observation,"/>
 <result pre="no study available analyzing this issue. Conclusions The incidence of" exact="viral" post="infections was high in allo-HCT patients while in auto-HCT"/>
 <result pre="study available analyzing this issue. Conclusions The incidence of viral" exact="infections" post="was high in allo-HCT patients while in auto-HCT patients"/>
 <result pre="infections was high in allo-HCT patients while in auto-HCT patients" exact="viral" post="infections were episodic. The most frequent viral infection after"/>
 <result pre="was high in allo-HCT patients while in auto-HCT patients viral" exact="infections" post="were episodic. The most frequent viral infection after allo-HCT"/>
 <result pre="in auto-HCT patients viral infections were episodic. The most frequent" exact="viral infection" post="after allo-HCT were CMV, BKV and EBV. Most viral"/>
 <result pre="auto-HCT patients viral infections were episodic. The most frequent viral" exact="infection" post="after allo-HCT were CMV, BKV and EBV. Most viral"/>
 <result pre="viral infection after allo-HCT were CMV, BKV and EBV. Most" exact="viral" post="infections occurred within the first 4 months after allo-HCT"/>
 <result pre="infection after allo-HCT were CMV, BKV and EBV. Most viral" exact="infections" post="occurred within the first 4 months after allo-HCT and"/>
 <result pre="4 months after allo-HCT and over 80% required pharmacotherapy or" exact="symptomatic" post="therapy. The median time of treatment of specific viral"/>
 <result pre="or symptomatic therapy. The median time of treatment of specific" exact="viral infection" post="ranged from 7 (for EBV) to 24 days (for"/>
 <result pre="symptomatic therapy. The median time of treatment of specific viral" exact="infection" post="ranged from 7 (for EBV) to 24 days (for"/>
 <result pre="infection-related mortality was observed in case of CMV infection, whereas" exact="primary" post="diagnosis did not influence survival from viral infection. The"/>
 <result pre="CMV infection, whereas primary diagnosis did not influence survival from" exact="viral infection." post="The risk factors for viral infections were allo-HCT, acute"/>
 <result pre="not influence survival from viral infection. The risk factors for" exact="viral" post="infections were allo-HCT, acute leukemia, a/cGVHD, MUD/MMUD vs MSD."/>
 <result pre="influence survival from viral infection. The risk factors for viral" exact="infections" post="were allo-HCT, acute leukemia, a/cGVHD, MUD/MMUD vs MSD. The"/>
 <result pre="viral infection. The risk factors for viral infections were allo-HCT," exact="acute" post="leukemia, a/cGVHD, MUD/MMUD vs MSD. The risk factor for"/>
 <result pre="a/cGVHD, MUD/MMUD vs MSD. The risk factor for death from" exact="viral infection" post="were CMV-IgG seropositivity in acute lymphoblastic leukemia recipients, MUD/MMUD"/>
 <result pre="MUD/MMUD vs MSD. The risk factor for death from viral" exact="infection" post="were CMV-IgG seropositivity in acute lymphoblastic leukemia recipients, MUD/MMUD"/>
 <result pre="factor for death from viral infection were CMV-IgG seropositivity in" exact="acute lymphoblastic leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
 <result pre="for death from viral infection were CMV-IgG seropositivity in acute" exact="lymphoblastic leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
 <result pre="death from viral infection were CMV-IgG seropositivity in acute lymphoblastic" exact="leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
 <result pre="lymphoblastic leukemia recipients, MUD/MMUD vs MSD. The incidence of EBV" exact="infection" post="requiring pre-emptive treatment with rituximab in allo-HSCT children was"/>
 <result pre="cases of EBV infection, these episodes were preceded by other" exact="viral infection" post="treated with antivirals, which did not prevent development of"/>
 <result pre="of EBV infection, these episodes were preceded by other viral" exact="infection" post="treated with antivirals, which did not prevent development of"/>
 <result pre="study was created on behalf of the Polish Society of" exact="Pediatric" post="Oncology and Hematology. The authors thanks to Mariusz Wysocki,"/>
 <result pre="aciclovir; ADV, adenovirus; a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="allo-, allogeneic; AML, acute myeloblastic leukemia; ANC, absolute neutrophil"/>
 <result pre="ADV, adenovirus; a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="allo-, allogeneic; AML, acute myeloblastic leukemia; ANC, absolute neutrophil"/>
 <result pre="versus host disease; ALL, acute lymphoblastic leukemia; allo-, allogeneic; AML," exact="acute" post="myeloblastic leukemia; ANC, absolute neutrophil count; ARAC, cytarabine; auto-,"/>
 <result pre="carmustine; BKV, polyoma BK virus; BM, bone marrow; CARV, community-acquired" exact="respiratory" post="virus; CI, confidence intervals; CIBMTR, Center for International Blood"/>
 <result pre="community-acquired respiratory virus; CI, confidence intervals; CIBMTR, Center for International" exact="Blood" post="and Marrow Transplant Research; CMV, cytomegalovirus; D, days; EBV,"/>
 <result pre="cytomegalovirus; D, days; EBV, Epstein–Barr virus; ECIL, European Conference on" exact="Infections" post="in Leukaemia; FCV, foscarnet; FLUAV, influenza A virus; FLUBV,"/>
 <result pre="influenza A virus; FLUBV, influenza B virus; GCV, ganciclovir; HBV," exact="hepatitis" post="B virus; HCT, hematopoietic cell transplantation; HD, Hodgkin lymphoma;"/>
 <result pre="ganciclovir; HBV, hepatitis B virus; HCT, hematopoietic cell transplantation; HD," exact="Hodgkin lymphoma;" post="HHV-6, human herpesvirus 6; hMPV, human metapneumovirus; HPIV, parainfluenza;"/>
 <result pre="6; hMPV, human metapneumovirus; HPIV, parainfluenza; HR, hazard ratio; HSV," exact="herpes" post="simplex virus; IQR, quartiles; MAC, myeloablative conditioning; MEL, melphalan;"/>
 <result pre="donor; MSD, matched sibling donor; MUD, matched unrelated donor; NHL," exact="Non-Hodgkin Lymphoma;" post="NoV, norovirus; PB, peripheral blood; PTLD, post-transplant lymphoproliferative disease;"/>
 <result pre="MUD, matched unrelated donor; NHL, Non-Hodgkin Lymphoma; NoV, norovirus; PB," exact="peripheral" post="blood; PTLD, post-transplant lymphoproliferative disease; PVB19, parvovirus B19; RhV,"/>
 <result pre="NHL, Non-Hodgkin Lymphoma; NoV, norovirus; PB, peripheral blood; PTLD, post-transplant" exact="lymphoproliferative disease;" post="PVB19, parvovirus B19; RhV, rhinovirus; RIC, reduced-intensity of conditioning;"/>
 <result pre="PVB19, parvovirus B19; RhV, rhinovirus; RIC, reduced-intensity of conditioning; RSV," exact="respiratory" post="syncytial virus; TBI, total body irradiation; VP, etoposide; VZV,"/>
 <result pre="rhinovirus; RIC, reduced-intensity of conditioning; RSV, respiratory syncytial virus; TBI," exact="total" post="body irradiation; VP, etoposide; VZV, varicella-zoster virus. Author Contributions"/>
 <result pre="to this article. References References 1.StyczynskiJ, CzyzewskiK, WysockiM, et al." exact="Increased" post="risk of infections and infection-related mortality in children undergoing"/>
 <result pre="References References 1.StyczynskiJ, CzyzewskiK, WysockiM, et al. Increased risk of" exact="infections" post="and infection-related mortality in children undergoing haematopoietic stem cell"/>
 <result pre="2018Available from:https://www.cibmtr.org. Accessed 1111, 2019. 3.CzyzewskiK, GalazkaP, Zalas-WiecekP, et al." exact="Infectious" post="complications in children with malignant bone tumors: a multicenter"/>
 <result pre="3.CzyzewskiK, GalazkaP, Zalas-WiecekP, et al. Infectious complications in children with" exact="malignant" post="bone tumors: a multicenter nationwide study. Infect Drug Resist."/>
 <result pre="al. Timeline, epidemiology, and risk factors for bacterial, fungal, and" exact="viral" post="infections in children and adolescents after allogeneic hematopoietic stem"/>
 <result pre="Timeline, epidemiology, and risk factors for bacterial, fungal, and viral" exact="infections" post="in children and adolescents after allogeneic hematopoietic stem cell"/>
 <result pre="children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol" exact="Blood" post="Marrow Transplant. 2013;19(1):94–101. doi:10.1016/j.bbmt.2012.08.01222922523 5.SrinivasanA, McLaughlinL, WangC, et al."/>
 <result pre="Marrow Transplant. 2013;19(1):94–101. doi:10.1016/j.bbmt.2012.08.01222922523 5.SrinivasanA, McLaughlinL, WangC, et al. Early" exact="infections" post="after autologous hematopoietic stem cell transplantation in children and"/>
 <result pre="the St. Jude experience. Transpl Infect Dis. 2014;16(1):90–97. doi:10.1111/tid.2014.16.issue-124256514 6.MarrKA." exact="Delayed" post="opportunistic infections in hematopoietic stem cell transplantation patients: a"/>
 <result pre="Jude experience. Transpl Infect Dis. 2014;16(1):90–97. doi:10.1111/tid.2014.16.issue-124256514 6.MarrKA. Delayed opportunistic" exact="infections" post="in hematopoietic stem cell transplantation patients: a surmountable challenge."/>
 <result pre="of donor epstein-barr virus serostatus on the incidence of graft-versus-host" exact="disease" post="in patients with acute leukemia after hematopoietic stem-cell transplantation:"/>
 <result pre="serostatus on the incidence of graft-versus-host disease in patients with" exact="acute" post="leukemia after hematopoietic stem-cell transplantation: a study from the"/>
 <result pre="on the incidence of graft-versus-host disease in patients with acute" exact="leukemia" post="after hematopoietic stem-cell transplantation: a study from the acute"/>
 <result pre="acute leukemia after hematopoietic stem-cell transplantation: a study from the" exact="acute" post="leukemia and infectious diseases working parties of the European"/>
 <result pre="leukemia after hematopoietic stem-cell transplantation: a study from the acute" exact="leukemia" post="and infectious diseases working parties of the European society"/>
 <result pre="hematopoietic stem-cell transplantation: a study from the acute leukemia and" exact="infectious diseases" post="working parties of the European society for blood and"/>
 <result pre="ReusserP, EinseleH, et al. Management of HSV, VZV and EBV" exact="infections" post="in patients with hematological malignancies and after SCT: guidelines"/>
 <result pre="and after SCT: guidelines from the Second European Conference on" exact="Infections" post="in Leukemia. Bone Marrow Transplant. 2009;43(10):757–770. doi:10.1038/bmt.2008.38619043458 9.LjungmanP, de"/>
 <result pre="al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8)" exact="infections" post="in patients with hematological malignancies and after SCT. Bone"/>
 <result pre="transplantation. Infect Dis Ther. 2018;7(1):1–16. doi:10.1007/s40121-017-0180-z 11.StyczynskiJ, GilL. Prevention of" exact="infectious" post="complications in pediatric HSCT. Bone Marrow Transplant. 2008;42(Suppl 2):S77–S81."/>
 <result pre="12.HirschHH, MartinoR, WardKN, BoeckhM, EinseleH, LjungmanP. Fourth European Conference on" exact="Infections" post="in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of"/>
 <result pre="in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human" exact="respiratory" post="syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin"/>
 <result pre="estimators. Stat Med. 1999;18(6):695–706. doi:10.1002/(ISSN)1097-025810204198 14.KaplanEL, MeierP. Nonparametric estimation from" exact="incomplete" post="observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452 15.MillerHK, BraunTM,"/>
 <result pre="Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452 15.MillerHK, BraunTM, StillwellT, et al." exact="Infectious" post="risk after allogeneic hematopoietic cell transplantation complicated by acute"/>
 <result pre="al. Infectious risk after allogeneic hematopoietic cell transplantation complicated by" exact="acute" post="graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(3):522–528. doi:10.1016/j.bbmt.2016.12.63028017733 16.HiwarkarP,"/>
 <result pre="allogeneic hematopoietic cell transplantation complicated by acute graft-versus-host disease. Biol" exact="Blood" post="Marrow Transplant. 2017;23(3):522–528. doi:10.1016/j.bbmt.2016.12.63028017733 16.HiwarkarP, GasparHB, GilmourK, et al."/>
 <result pre="Transplant. 2017;23(3):522–528. doi:10.1016/j.bbmt.2016.12.63028017733 16.HiwarkarP, GasparHB, GilmourK, et al. Impact of" exact="viral" post="reactivations in the era of pre-emptive antiviral drug therapy"/>
 <result pre="Bone Marrow Transplant. 2013;48(6):803–808. doi:10.1038/bmt.2012.22123178547 17.ChoiJH, ChoiEH, KangHJ, et al." exact="Respiratory" post="viral infections after hematopoietic stem cell transplantation in children."/>
 <result pre="Marrow Transplant. 2013;48(6):803–808. doi:10.1038/bmt.2012.22123178547 17.ChoiJH, ChoiEH, KangHJ, et al. Respiratory" exact="viral" post="infections after hematopoietic stem cell transplantation in children. J"/>
 <result pre="Transplant. 2013;48(6):803–808. doi:10.1038/bmt.2012.22123178547 17.ChoiJH, ChoiEH, KangHJ, et al. Respiratory viral" exact="infections" post="after hematopoietic stem cell transplantation in children. J Korean"/>
 <result pre="la CamaraR, RobinC, et al. Guidelines for the management of" exact="cytomegalovirus infection" post="in patients with haematological malignancies and after stem cell"/>
 <result pre="CamaraR, RobinC, et al. Guidelines for the management of cytomegalovirus" exact="infection" post="in patients with haematological malignancies and after stem cell"/>
 <result pre="after stem cell transplantation from the 2017 European Conference on" exact="Infections" post="in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260–e272. doi:10.1016/S1473-3099(19)30107-031153807"/>
 <result pre="for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic" exact="cystitis" post="in haematopoietic stem cell transplant recipients. J Antimicrob Chemother."/>
 <result pre="et al. European guidelines for diagnosis and treatment of adenovirus" exact="infection" post="in leukemia and stem cell transplantation: summary of ECIL-4"/>
 <result pre="European guidelines for diagnosis and treatment of adenovirus infection in" exact="leukemia" post="and stem cell transplantation: summary of ECIL-4 (2011). Transpl"/>
 <result pre="2012;14(6):555–563. doi:10.1111/tid.2012.14.issue-623146063 21.MikulskaM, Del BonoV, GandolfoN, et al. Epidemiology of" exact="viral" post="respiratory tract infections in an outpatient haematology facility. Ann"/>
 <result pre="doi:10.1111/tid.2012.14.issue-623146063 21.MikulskaM, Del BonoV, GandolfoN, et al. Epidemiology of viral" exact="respiratory" post="tract infections in an outpatient haematology facility. Ann Hematol."/>
 <result pre="Del BonoV, GandolfoN, et al. Epidemiology of viral respiratory tract" exact="infections" post="in an outpatient haematology facility. Ann Hematol. 2014;93(4):669–676. doi:10.1007/s00277-013-1912-024097084"/>
 <result pre="facility. Ann Hematol. 2014;93(4):669–676. doi:10.1007/s00277-013-1912-024097084 22.LjungmanP, WardKN, CrooksBN, et al." exact="Respiratory" post="virus infections after stem cell transplantation: a prospective study"/>
 <result pre="Hematol. 2014;93(4):669–676. doi:10.1007/s00277-013-1912-024097084 22.LjungmanP, WardKN, CrooksBN, et al. Respiratory virus" exact="infections" post="after stem cell transplantation: a prospective study from the"/>
 <result pre="infections after stem cell transplantation: a prospective study from the" exact="Infectious" post="Diseases Working Party of the European Group for Blood"/>
 <result pre="after stem cell transplantation: a prospective study from the Infectious" exact="Diseases" post="Working Party of the European Group for Blood and"/>
 <result pre="the Infectious Diseases Working Party of the European Group for" exact="Blood" post="and Marrow Transplantation. Bone Marrow Transplant. 2001;28(5):479–484. doi:10.1038/sj.bmt.170313911593321 23.EngelhardD,"/>
 <result pre="and management of influenza in hematopoietic stem cell transplantation and" exact="leukemia" post="patients: summary of ECIL-4 (2011), on behalf of ECIL,"/>
 <result pre="Infect Dis. 2013;15(3):219–232. doi:10.1111/tid.2013.15.issue-323363310 24.FlerlageT, HaydenR, CrossSJ, et al. Rotavirus" exact="infection" post="in pediatric allogeneic hematopoietic cell transplant recipients: clinical course"/>
 <result pre="Dis J. 2018;37(2):176–181. doi:10.1097/INF.000000000000174028787390 25.van KraaijMG, DekkerAW, VerdonckLF, et al." exact="Infectious" post="gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic"/>
 <result pre="et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in" exact="adult" post="allogeneic and autologous stem cell transplant recipients. Bone Marrow"/>
 <result pre="Bone Marrow Transplant. 2000;26(3):299–303. doi:10.1038/sj.bmt.170248410967569 26.RoblesJD, CheukDK, HaSY, ChiangAK, ChanGC." exact="Norovirus infection" post="in pediatric hematopoietic stem cell transplantation recipients: incidence, risk"/>
 <result pre="Marrow Transplant. 2000;26(3):299–303. doi:10.1038/sj.bmt.170248410967569 26.RoblesJD, CheukDK, HaSY, ChiangAK, ChanGC. Norovirus" exact="infection" post="in pediatric hematopoietic stem cell transplantation recipients: incidence, risk"/>
 <result pre="stem cell transplantation recipients: incidence, risk factors, and outcome. Biol" exact="Blood" post="Marrow Transplant. 2012;18(12):1883–1889. doi:10.1016/j.bbmt.2012.07.00522796532 27.WilliamsD. Treatment of rotavirus-associated diarrhea"/>
 <result pre="Biol Blood Marrow Transplant. 2012;18(12):1883–1889. doi:10.1016/j.bbmt.2012.07.00522796532 27.WilliamsD. Treatment of rotavirus-associated" exact="diarrhea" post="using enteral immunoglobulins for pediatric stem cell transplant patients."/>
 <result pre="Pharm Pract. 2015;21(3):238–240. doi:10.1177/107815521452231324658362 28.LinR, LiuQ. Diagnosis and treatment of" exact="viral" post="diseases in recipients of allogeneic hematopoietic stem cell transplantation."/>
 <result pre="29.CzyzewskiK, StyczynskiJ, KrenskaA, et al. Intrathecal therapy with rituximab in" exact="central nervous system" post="involvement of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2013;54(3):503–506. doi:10.3109/10428194.2012.71834222873830"/>
 <result pre="Intrathecal therapy with rituximab in central nervous system involvement of" exact="post-transplant lymphoproliferative disorder." post="Leuk Lymphoma. 2013;54(3):503–506. doi:10.3109/10428194.2012.71834222873830 30.StyczynskiJ, EinseleH, GilL, LjungmanP. Outcome"/>
 <result pre="2013;54(3):503–506. doi:10.3109/10428194.2012.71834222873830 30.StyczynskiJ, EinseleH, GilL, LjungmanP. Outcome of treatment of" exact="Epstein-Barr virus-related post-transplant lymphoproliferative disorder" post="in hematopoietic stem cell recipients: a comprehensive review of"/>
 <result pre="30.StyczynskiJ, EinseleH, GilL, LjungmanP. Outcome of treatment of Epstein-Barr virus-related" exact="post-transplant lymphoproliferative disorder" post="in hematopoietic stem cell recipients: a comprehensive review of"/>
</results>
